Long-term bisphosphonate therapy is associated with increased risk ofosteonecrosis of the jaw (ONJ). In a retrospective analysis, a 16% ONJ incidence was reported in patients receiving bisphosphonates with anti-angiogenic therapy(bevacizumab or sunitinib) for bone metastases from breast, colon, or renal cell cancers. To assess ONJ incidence with bevacizumab, we analysed data from 3,560patients receiving bevacizumab-containing therapy for locally recurrent ormetastatic breast cancer (LR/MBC) in two double-blind, randomised trials (AVADOand RIBBON-1) and a large, non-randomised safety study (ATHENA). The overallincidence of ONJ with bevacizumab was 0.3% in the blinded phase of the tworandomised trials and 0.4% in the single-arm study. There was a trend towardsincreased ONJ incidence in patients who received bisphosphonate therapy versusthose with no bisphosphonate exposure (0.9 vs. 0.2%, respectively, in the pooled analysis of the randomised trials; 2.4 vs. 0%, respectively, in ATHENA). Inconclusion, this is the largest analysis of ONJ in patients receiving bevacizumabfor LR/MBC. The 0.3-0.4% incidence is considerably lower than previouslysuggested with anti-angiogenic therapy in a small retrospective analysis. Therisk of ONJ appeared to be increased in patients exposed to bisphosphonates, apattern consistent with observations before the introduction of anti-angiogenictherapy to breast cancer management. The 0.9-2.4% incidence seen inbisphosphonate-exposed patients receiving bevacizumab is within the 1-6% rangereported for bisphosphonates alone. Good oral hygiene, dental examination, andavoidance of invasive dental procedures remain important in patients receivingbisphosphonates, irrespective of bevacizumab administration.
|Data di pubblicazione:||2010|
|Titolo:||Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.|
|Autore/i:||Guarneri, Valentina; Miles, D; Robert, N; Di√©ras, V; Glaspy, J; Smith, I; Thomssen, C; Biganzolil, ; Taran, T; Conte, Pierfranco|
|Codice identificativo ISI:||WOS:000278615800020|
|Codice identificativo Scopus:||2-s2.0-77953534421|
|Citazione:||Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer / Guarneri, Valentina; Miles, D; Robert, N; Di√©ras, V; Glaspy, J; Smith, I; Thomssen, C; Biganzolil, ; Taran, T; Conte, Pierfranco. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - STAMPA. - 122(2010), pp. 181-188.|
|Tipologia||Articolo su rivista|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris